(Reuters) - Shares of VeriChip Corp (CHIP.O)
tripled after the company said it had been granted an exclusive
license to two patents, which will help it to develop
implantable virus detection systems in humans.
The patents, held by VeriChip partner Receptors LLC, relate
to biosensors that can detect the H1N1 and other viruses, and
biological threats such as methicillin-resistant Staphylococcus
aureus, VeriChip said in a statement.
The technology will combine with VeriChip's implantable
radio frequency identification devices to develop virus triage
The triage system will provide multiple levels of
identification -- the first will identify the agent as virus or
non-virus, the second level will classify the virus and alert
the user to the presence of pandemic threat viruses and the
third level will identify the precise pathogen, VeriChip said
in a white paper published May 7, 2009.
Shares of VeriChip were up 186 percent at $3.28 Monday late
afternoon trade on Nasdaq. They had touched a year high of
$3.43 earlier in the session.
(Reporting by Mansi Dutta in Bangalore; Editing by Mike Miller
and Anil D'Silva)